

Special Issue

Advances in Cancer Epigenetics

Message from the Guest Editors

The alteration of the epigenome profiles is a hallmark of virtually all cancers. New advances in cancer epigenetics highlight the complexity and intricacy of various epigenetic modifications from early steps of neoplasia, cancer stem cell maintenance, and metastasis. The importance of metabolism alterations and toxicant exposure play a clear role in carcinogenesis and response to therapy. The understating of the coordination between active and repressive epigenetic marks has increased considerably in recent years and leads to tailored epigenetic therapeutics, which represent the future of precision medicine.

Guest Editors

Prof. Dr. Noël J. Raynal

Département de Pharmacologie et de Physiologie, Université de Montréal and Sainte-Justine University Hospital Research Center, Montréal, QC, Canada

Prof. Dr. Serge McGraw

1. Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, QC, Canada
2. Centre de recherche du CHU Sainte-Justine, Montreal, QC, Canada
3. Department of Obstetrics and Gynecology, Université de Montréal, Montreal, QC, Canada

Deadline for manuscript submissions

closed (15 June 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/106181

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)